{
    "nct_id": "NCT03592888",
    "official_title": "Pilot Study of Mature Dendritic Cell Vaccination Against Mutated KRAS in Patients With Resectable Pancreatic Cancer",
    "inclusion_criteria": "* Pathologically-confirmed KRAS(G12D-), KRAS(G12V-), KRAS(G12R-) or KRAS(G12C-mutated) pancreatic ductal adenocarcinoma who are at high risk of relapse and have no evidence of disease.\n* Expression of one or more of the following HLA class I alleles: HLA-A02, HLA-A03, HLA-A11, HLA-B07 and HLA-C08.\n* Male or female, age 18+\n* ECOG performance status 0-1\n* Certain required laboratory values, performed within 14 days prior to consent\n* Subjects of reproductive potential must agree to use a medically accepted birth control method during the trial and for at least two months following the trial.\n* Provide written informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with more than two lines of cytotoxic chemotherapy. Radiotherapy is not considered a line of therapy.\n* Prior malignancy (except non-melanoma skin cancer) within 3 years.\n* Pregnant or nursing women.\n* Concurrent treatment with systemic immunosuppressants, including corticosteroids (e.g prednisone), calcineurin inhibitors (e.g tacrolimus, cyclosporine), antiproliferative agents (e.g mycophenolate mofetil, azathioprine) within 2 weeks of eligibility confirmation. Local (inhaled or topical) steroids or replacement dose prednisone (â‰¤ 10 mg daily) are permitted.\n* Known chronic viral infections including hepatitis B, hepatitis C, and HIV.\n* Known allergy to eggs.\n* Prior history of uveitis or autoimmune inflammatory eye disease.\n* Uncontrolled intercurrent illness.\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.",
    "miscellaneous_criteria": ""
}